AstraZeneca pays $68.5 million in Seroquel marketing case

Share this article:

Pharmaceutical giant AstraZeneca on Thursday agreed to pay $68.5 million to settle allegations that it inappropriately marketed the drug Seroquel for off-label uses, multiple states' authorities announced.

The settlement will be split among 37 states, making it the largest multi-state settlement from a pharmaceutical company in U.S. history, according to the Bureau of National Affairs. States had charged AstraZeneca with marketing the drug, which is approved to treat schizophrenia and bipolar disorder, for use on elderly patients with dementia, among others. In the lawsuit, states also claimed the company hid the nature of the drug's side effects from healthcare providers.

AstraZeneca has denied any wrongdoing. A company spokesman said that the settlement was paid in order to “bring these matters to a close and move forward with our business of providing medicines to patients.” Last year, the company paid the U.S. a $502 million settlement in a separate case involving the marketing of Seroquel.

Share this article:

More in News

Skilled nursing facility trends contribute to improved Medicare outlook, Congressional report says

The Medicare trust fund is on track to remain solvent until 2030, trustees of the program stated in a Congressional report released Monday. This improved outlook is due in part to revised expectations about the case mix in skilled nursing facilities.

House bill would define, promote coordinated long-term care services

A bill introduced in the House of Representatives would target improved care coordination for seniors, also adding it under the Older Americans Act.

Seize the day: Tech Awards deadline is tomorrow

Seize the day: Tech Awards deadline is tomorrow

The final countdown has begun: Long-term care providers have less than 48 hours to enter the third annual McKnight's Excellence in Technology Awards. Submissions will be accepted through July 30.